Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...
Money Morning2h
Three Stocks: Super Micro Computer, Dell, and Eli Lilly
Over the last month, Dell and Super Micro have been sparring in the headlines with new product releases. Just two weeks ago, ...
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St.
The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales
Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent company ...
MedPage Today4h
Weight Loss After Bariatric Surgery in Teens Persisted at 10 Years
For adolescents, weight loss after bariatric surgery was durable out to 10 years, data from the Teen Longitudinal Assessment ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...